Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 13,270 Shares

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 13,270 shares of Pliant Therapeutics stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $148,624.00. Following the transaction, the general counsel now owns 80,774 shares in the company, valued at $904,668.80. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Mike Ouimette also recently made the following trade(s):

• On Wednesday, January 22nd, Mike Ouimette sold 10,230 shares of Pliant Therapeutics stock. The shares were sold at an average price of $10.99, for a total value of $112,427.70.

Pliant Therapeutics Trading Up 2.0 %

Shares of PLRX stock opened at $11.14 on Friday. Pliant Therapeutics, Inc. has a 12-month low of $10.22 and a 12-month high of $18.92. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09. The stock’s 50-day moving average price is $13.18 and its 200-day moving average price is $13.06. The stock has a market capitalization of $677.87 million, a price-to-earnings ratio of -3.34 and a beta of 1.05.

Pliant Therapeutics (NASDAQ:PLRX) last issued its earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.04. Equities research analysts predict that Pliant Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Pliant Therapeutics

Several large investors have recently made changes to their positions in the company. Great Point Partners LLC increased its stake in Pliant Therapeutics by 42.4% during the second quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock worth $28,346,000 after acquiring an additional 785,000 shares during the last quarter. State Street Corp increased its stake in Pliant Therapeutics by 1.9% during the third quarter. State Street Corp now owns 1,402,730 shares of the company’s stock worth $15,725,000 after acquiring an additional 26,610 shares during the last quarter. Geode Capital Management LLC increased its stake in Pliant Therapeutics by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,318,308 shares of the company’s stock worth $14,781,000 after acquiring an additional 31,221 shares during the last quarter. Franklin Resources Inc. increased its stake in Pliant Therapeutics by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,039,904 shares of the company’s stock worth $11,657,000 after acquiring an additional 14,913 shares during the last quarter. Finally, Fernwood Investment Management LLC increased its stake in Pliant Therapeutics by 3.4% during the third quarter. Fernwood Investment Management LLC now owns 513,136 shares of the company’s stock worth $5,752,000 after acquiring an additional 16,850 shares during the last quarter. 97.30% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Pliant Therapeutics in a research report on Friday, November 8th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.